$KLTO News
Last published 5mo ago
- 5mo agoGRMLKLTOMPCRMLWhy a $35 Million Greenland Rare Earth Deal Just Put One Small-Cap on Every Investor's RadarPR NewswireUSA NEWS GROUP News Commentary — The rare earth sector just got a fresh jolt of momentum. Rare earth elements — the 17 metals that power EV motors,...
- 8mo agoKLTOKlotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRMLPR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and...
- 8mo agoKLTOKlotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026PR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd...
- 8mo agoKLTOKLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDORPR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or...
- 8mo agoKLTOKlotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)PR NewswireKlotho Neurosciences, Inc. ("Klotho" or the Company) announces the development of two genomics-based diagnostic tests that will be utilized in...
- 8mo agoKLTOKlotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene SequencePR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO) ("Klotho" or the Company) announces the acceptance of 18 claims within a patent application filed in...
- 10mo agoKLTOKlotho Neurosciences to Present at the Biotech Showcase 2026PR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company"), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will...
- 1y agoKLTOKlotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' AwardPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO ) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has been selected as winner of ...
- 1y agoKLTOKlotho Neurosciences CEO to Attend Longevity Biotech 2025 in BostonPR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company") a U.S.-based biogenetics company, announces that members of its leadership team ...
- 1y agoKLTOKlotho Neurosciences Announces Expiration of Letter of IntentPR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company") today announced that its Letter of Intent with Turn Biotechnologies was allowed ...
- 1y agoKLTOKlotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma PartnershipPR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho" or "the Company") today announced it has signed a Letter of Intent (LOI) to acquire select assets...
- 1y agoKLTOKlotho Neurosciences CEO to Attend Inaugural Conference & Scientific SeminarPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for...
- 1y agoKLTOKlotho Neurosciences CEO to Attend Inaugural Conference & Scientific SeminarPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for...
- 1y agoKLTOKlotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease MarketPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for...
- 1y agoKLTOKlotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform TechnologyPR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202...
- 1y agoKLTOUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced that it is evaluating the acquisition of several complementary...
- 1y agoKLTOKlotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary...
- 1y agoKLTOKlotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy AssetsPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven ...
- 1y agoKLTOKlotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity RulesPR NewswireKlotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative...
- 1y agoKLTOKlotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")PR NewswireKlotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related...
- 1y agoKLTOKlotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALSPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation...
- 1y agoKLTOKlotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived PopulationPR NewswireKlotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological...
- 1y agoKLTOKLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMSPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho," "KLTO," or the "Company") today announced that on June 13, 2025, it entered into a Termination...
- 1y agoKlothoKLTOKLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENTPR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised...
- 1y agoKLTOKLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")PR NewswireKlotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential...
- 1y agoKLTOKlotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San FranciscoGlobeNewswireNEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS),
- 1y agoKLTODr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory BoardGlobeNewswireNEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS),
- 1y agoKLTOFormer Merck USA President Joins Klotho Neurosciences' Board of DirectorsGlobeNewswireNEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including
- 2y agoKLTODr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific AdvisorGlobeNewswireNEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to
- 2y agoKLTOCo-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho NeurosciencesGlobeNewswireNEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the
- 2y agoKLTODr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)GlobeNewswireNEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting
- 2y agoWENAKLTOANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.GlobeNewswireNEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website,